Elevance Health, Inc.

Valuation Analysis

About the Company

Elevance Health, Inc., together with its subsidiaries, operates as a health benefits company in the United States. The company operates in four segments: Health Benefits, CarelonRx, Carelon Services, and Corporate & Other. It offers a variety of health plans and services to individual, employer group risk-based and fee-based, BlueCard, Medicare, Medicaid, and FEP members; health products; a broad array of fee-based administrative managed care services; and specialty and other insurance products and services, such as stop loss, dental, vision, and supplemental health insurance benefits. The company also operates in the pharmacy services business; and markets and offers pharmacy services, including home delivery and specialty pharmacies, claims adjudication, formulary management, pharmacy ne

Elevance Health, Inc. Stock at a Glance

Elevance Health, Inc. (ELV) is currently trading at $404.07 with a market capitalization of $87.7B. The trailing P/E ratio stands at 17.12x, with a forward P/E of 13.82x. The 52-week range spans from $273.71 to $426.98; the current price is 5.4% below the yearly high. Year-over-year revenue growth stands at +2.6%. The net profit margin stands at 2.62%.

💰 Dividend

Elevance Health, Inc. pays an annual dividend of $6.88 per share, representing a yield of 1.7%. The payout ratio stands at 29.03%.

📊 Analyst Rating

21 analysts rate Elevance Health, Inc. (ELV) on consensus: Buy. The average price target is $415.81, implying +2.91% from the current price. Analyst price targets range from $331.00 to $498.00.

Elevance Health, Inc.: The Investment Case in Detail

Elevance Health, Inc. (ELV) operates in the Healthcare — specifically Healthcare Plans — and is headquartered in United States. Below is a structured read of the investment case built directly from the latest fundamentals, valuation multiples, analyst positioning and smart-money flows. Each section translates raw numbers into the investment logic they imply, so you can decide whether the risk/reward fits your portfolio.

The Bull Case

Our valuation screen flags the stock as undervalued relative to its fundamentals — multiples are running below where the cash flow profile would normally justify.

The Bear Case

Revenue growth has slowed to just 2.6%, which is below nominal GDP — the business is no longer outgrowing the broader economy. With a net margin of just 2.62%, the business has little room to absorb cost shocks or pricing pressure — a single bad quarter can swing the company to a loss.

Valuation in Context

The PEG ratio at 1.48 sits in the reasonable zone — the price tag is roughly aligned with the company's growth profile, neither punishing nor euphoric. The EV/EBITDA multiple of 9.68x is below the historical equity-market average — strategic acquirers would find the cash-flow profile attractive at this level.

What to Watch Next

• The forward P/E of 13.82x is meaningfully below the trailing 17.12x — analysts expect earnings to step up; the next earnings release is the test.

Investment Thesis: Strengths & Weaknesses

Technical Snapshot

Price trades above both the 50- and 200-day moving averages, with 50d above 200d — a classic bullish setup (golden-cross alignment).

Risk Profile

The data points to relatively defensive market behavior.

Trading Data

💵 Dividend Info

Related Stocks in the Same Sector

Where can I buy Elevance Health, Inc.?

Compare top-rated brokers — low fees, trusted providers, fully regulated.